CD8A and neoplasm: The use of a Gal-1-targeting DNA aptamer (AP-74 M-545) prevented the binding of Gal-1 to CD45 and increased CD4+ and CD8+ T cell influx, suppressing tumour growth in immunocompetent but not in immunocompromised mice (161).